DALLAS (Feb. 10, 2012) — In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ™, in Dallas, Texas, researchers will report findings that show that in women with acute postpartum anemia, due to excessive blood loss during delivery, red blood cell transfusion led to a statistically significant decrease in physical fatigue. While excessive blood loss during delivery caused severe physical fatigue, the effect of red blood cell transfusion on this fatigue was small.
This study, RBC Transfusion Leads to an Improvement of Physical Fatigue in Women with Acute Postpartum Anemia: the WOMB Study, is the first study worldwide to investigate the blood transfusion policy among postpartum women, a very specific population of mostly healthy, young women who develop an acute anemia due to postpartum hemorrhage.
"We believe that the difference in physical fatigue between blood transfusion and expectant management, i.e. no transfusion, is clinically acceptable and expectant management should therefore be preferred," said Johannes J. Duvekot, MD, PhD, with Erasmus MC, Obstetrics & Gynecology, Rotterdam, Netherlands, and one of the study's authors. "Blood transfusion should be given based on clinical symptoms and not on blood values only."
Duvekot and his colleagues investigated whether a red blood cell transfusion improved physical fatigue in postpartum anemic women, due to excessive blood loss during delivery, without severe physical complaints. Women who participated in the Netherlands nationwide study were randomly allocated to red blood cell transfusion or expectant management. They were followed for six weeks, in which they reported on their quality of life, including physical fatigue, by completing questionnaires.
The results of the study show that excessive blood loss during delivery caused severe physical fatigue. Red blood cell transfusion only mildly improved this fatigue. Therefore, in patients with acute anemia due to postpartum hemorrhage, who are hemodynamically stable, an expectant management is preferred.
In addition to Duvekot, the study was conducted by Babette W. Prick and Eric A.P. Steegers, Erasmus MC, Obstetrics & Gynecology, Rotterdam, Netherlands; A.J. Gerard Jansen, Erasmus MC, Internal Medicine, Rotterdam, Netherlands; Wim C.J. Hop, Erasmus MC, Biostatistics, Rotterdam, Netherlands; Marie-Louise Essink-Bot, Academic Medical Center, Public Health, Amsterdam, Netherlands; Carin A. Uyl-de Groot, Erasmus University, Institute for Medical Technology Assessment, Rotterdam, Netherlands; Dimitri N.M. Papatsonis, Amphia Hospital, Obstetrics & Gynecology, Breda, Netherlands; Bettina M.C. Akerboom, Albert Schweitzer Hospital, Obstetrics & Gynecology, Dordrecht, Netherlands; Godfried C.H. Metz, Ikazia Hospital, Obstetrics & Gynecology, Rotterdam, Netherlands; Henk A. Bremer, Reinier de Graaf Hospital, Obstetrics & Gynecology, Rotterdam, Netherlands; Aren J. van Loon, Martini Hospital, Obstetrics & Gynecology, Groningen, Netherlands; Rob H. Stigter, Deventer Hospital, Obstetrics & Gynecology, Deventer, Netherlands; Joris A.M. van der Post, Academic Medical Center, Obstetrics & Gynecology, Amsterdam, Netherlands; Marcel van Alphen, Flevo Hospital, Obstetrics & Gynecology, Almere, Netherlands; Martina Porath, Maxima Medical Center, Department of Obstetrics and Gynecology, Veldhoven, Netherlands; Robbert J.P. Rijnders, Jeroen Bosch Hospital, Obstetrics and Gynecology, 's-Hertogenbosch, Netherlands; Marc E.A. Spaanderman, University Medical Center Nijmegen St Radboud, Obstetrics and Gynecology, Nijmegen, Netherlands; Daniela H. Schippers, Canisius Wilhelmina Hospital, Obstetrics and Gynecology, Nijmegen, Netherlands; Kitty W.M. Bloemenkamp, Leiden University Medical Center, Obstetrics, Leiden, Netherlands; Kim E. Boers, Bronovo Hospital, Obstetrics and Gynecology, 's-Gravenhage, Netherlands; Hubertina C.J. Scheepers, University Hospital Maastricht, Obstetrics and Gynecology, Maastricht, Netherlands; Frans J.M.E. Roumen, Atrium MC, Obstetrics and Gynecology, Heerlen, Netherlands; Anneke Kwee, Dutch consortium AMPHIA trial, Netherlands; Nico W.E. Schuitemaker, Diakonessenhuis, Obstetrics and Gynecology, Utrecht, Netherlands; Ben Willem J. Mol, Academic Medical Center, Obstetrics & Gynecology, Amsterdam, Netherlands; and Dick J. van Rhenen, Sanquin Blood Supply Foundation, Transfusion medicine, Rotterdam, Netherlands.
A copy of the abstract is available at http://www.smfmnewsroom.org/annual-meeting/2011-meeting-abstracts/. For interviews please contact Vicki Bendure at Vicki@bendurepr.com, 540-687-3360 (office) or 202-374-9259 (cell), or Jacqueline Boggess at jacqueline@bendurepr.com, 540-687-5399 (office) or 202-738-3054 (cell).
The Society for Maternal-Fetal Medicine (est. 1977) is a non-profit membership group for obstetricians/gynecologists who have additional formal education and training in maternal-fetal medicine. The society is devoted to reducing high-risk pregnancy complications by providing continuing education to its 2,000 members on the latest pregnancy assessment and treatment methods. It also serves as an advocate for improving public policy, and expanding research funding and opportunities for maternal-fetal medicine. The group hosts an annual scientific meeting in which new ideas and research in the area of maternal-fetal medicine are unveiled and discussed. For more information, visit www.smfm.org or www.facebook.com/SocietyforMaternalFetalMedicine.